Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
$1.86
-6.8%
$1.94
$1.10
$8.88
$68.63M-0.9913,247 shs83,940 shs
ICL Group Ltd stock logo
ICL
ICL Group
$6.63
+0.1%
$6.35
$3.79
$6.95
$8.70B1.15810,906 shs581,417 shs
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
$0.00
$0.00
$0.00
N/AN/AN/A277,372 shs
Unigold Inc. stock logo
UGD
Unigold
C$0.09
+12.5%
C$0.08
C$0.04
C$0.13
C$24.68M1.27130,233 shs477,500 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
+9.42%+12.46%+0.81%-12.12%-75.96%
ICL Group Ltd stock logo
ICL
ICL Group
-0.08%+4.32%-1.12%+10.47%+42.14%
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
0.00%0.00%0.00%0.00%0.00%
Unigold Inc. stock logo
UGD
Unigold
+14.29%+14.29%-5.88%-5.88%+23.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
1.5757 of 5 stars
3.53.00.00.01.80.00.0
ICL Group Ltd stock logo
ICL
ICL Group
2.2004 of 5 stars
1.03.02.50.04.10.02.5
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
N/AN/AN/AN/AN/AN/AN/AN/A
Unigold Inc. stock logo
UGD
Unigold
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
3.00
Buy$9.00383.87% Upside
ICL Group Ltd stock logo
ICL
ICL Group
2.00
Hold$6.751.89% Upside
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
0.00
N/AN/AN/A
Unigold Inc. stock logo
UGD
Unigold
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PRX, ANL, UGD, and ICL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/5/2025
ICL Group Ltd stock logo
ICL
ICL Group
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $7.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
$5M13.73N/AN/AN/A
ICL Group Ltd stock logo
ICL
ICL Group
$6.87B1.27$1.01 per share6.54$4.59 per share1.44
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
N/AN/AN/AN/AN/AN/A
Unigold Inc. stock logo
UGD
Unigold
N/AN/AC$0.00 per share32.50C$0.00 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
-$104.87MN/A0.00N/AN/AN/AN/AN/A8/8/2025 (Estimated)
ICL Group Ltd stock logo
ICL
ICL Group
$647M$0.3121.3715.777.105.83%8.31%4.39%8/13/2025 (Estimated)
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Unigold Inc. stock logo
UGD
Unigold
-C$2.86M-C$0.01N/AN/AN/A-295.00%-74.41%N/A

Latest PRX, ANL, UGD, and ICL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q1 2025
ICL Group Ltd stock logo
ICL
ICL Group
$0.07$0.09+$0.02$0.07$1.82 billion$1.77 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
N/AN/AN/AN/AN/A
ICL Group Ltd stock logo
ICL
ICL Group
$0.162.42%-3.46%51.61%N/A
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
N/AN/AN/AN/AN/A
Unigold Inc. stock logo
UGD
Unigold
N/A4.42%N/AN/AN/A

Latest PRX, ANL, UGD, and ICL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/30/2025
ICL Group Ltd stock logo
ICL
ICL Group
quarterly$0.04262.8%6/4/20256/4/20256/18/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
N/A
1.85
N/A
ICL Group Ltd stock logo
ICL
ICL Group
0.30
1.56
0.91
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
N/AN/AN/A
Unigold Inc. stock logo
UGD
Unigold
N/A
2.31
0.61

Institutional Ownership

CompanyInstitutional Ownership
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
35.21%
ICL Group Ltd stock logo
ICL
ICL Group
13.38%
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
N/A
Unigold Inc. stock logo
UGD
Unigold
0.11%

Insider Ownership

CompanyInsider Ownership
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
N/A
ICL Group Ltd stock logo
ICL
ICL Group
0.27%
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
N/A
Unigold Inc. stock logo
UGD
Unigold
10.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adlai Nortye Ltd. stock logo
ANL
Adlai Nortye
12736.90 millionN/ANot Optionable
ICL Group Ltd stock logo
ICL
ICL Group
13,2001.31 billion1.31 billionOptionable
Pharmaceutical Resources stock logo
PRX
Pharmaceutical Resources
N/AN/AN/ANot Optionable
Unigold Inc. stock logo
UGD
Unigold
N/A274.26 millionN/ANot Optionable

Recent News About These Companies

Off-market insider buying at Unigold (UGD)
Unigold Announces TSXV Approves Warrant Extensions
Unigold Extends Expiry Dates for Share Warrants
Portland, OR Weather Conditions
UGD:CA Unigold Inc.
Closing Bell: Unigold Inc down on Friday (UGD)
Closing Bell: Unigold Inc flat on Monday (UGD)
Unigold Inc: TSX-V Approves Warrant Extension

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adlai Nortye stock logo

Adlai Nortye NASDAQ:ANL

$1.86 -0.14 (-6.77%)
Closing price 03:58 PM Eastern
Extended Trading
$1.82 -0.04 (-2.15%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

ICL Group stock logo

ICL Group NYSE:ICL

$6.62 +0.01 (+0.08%)
Closing price 03:59 PM Eastern
Extended Trading
$6.64 +0.01 (+0.15%)
As of 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ICL Group Ltd, together with its subsidiaries, operates as a specialty minerals and chemicals company worldwide. It operates in four segments: Industrial Products, Potash, Phosphate Solutions, and Growing Solutions. The Industrial Products segment produces bromine out of a solution that is a by-product of the potash production process, as well as bromine-based compounds; produces various grades of potash, salt, magnesium chloride, and magnesia products; and produces and markets phosphorous-based flame retardants and other phosphorus-based products. The Potash segment extracts potash from the Dead Sea; mines and produces potash and salt; produces polysulphate; produces, markets, and sells magnesium and magnesium alloys, as well as related by-products, including chlorine and sylvinite; and sells salt. The Phosphate Solutions segment uses phosphate commodity products to produce specialty products; produces and markets phosphate-based fertilizers, as well as sulphuric acid, green phosphoric acid, and phosphate fertilizers; and manufactures thermal phosphoric acid for various industrial end markets, such as oral care, cleaning products, paints and coatings, water treatment, asphalt modification, construction, and metal treatment. It also develops and produces functional food ingredients and phosphate additives for use in the processed meat, poultry, seafood, dairy, beverage, and baked goods markets; and produces milk and whey proteins for the food ingredients industry. The Growing Solutions segment develops, manufactures, markets, and sells fertilizers based primarily on nitrogen, potash, and phosphate, including water soluble specialty, liquid, soluble, and controlled-release fertilizers. It sells its products through marketing companies, agents, and distributors. The company was formerly known as Israel Chemicals Ltd. and changed its name to ICL Group Ltd in May 2020. The company was founded in 1968 and is headquartered in Tel Aviv, Israel.

Pharmaceutical Resources stock logo

Pharmaceutical Resources NYSE:PRX

Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.

Unigold stock logo

Unigold CVE:UGD

C$0.09 +0.01 (+12.50%)
As of 03:31 PM Eastern

Unigold Inc., a junior natural resource company, focuses on exploring and developing gold projects in Canada and the Dominican Republic. The company also explores for copper, silver, and zinc deposits. It holds an 100% interest in the Neita property covering an area of 21,031 hectares in the Dominican Republic; and the Candelones Oxide project situated in the Dominican Republic. The company was formerly known as Caribgold Resources Inc. and changed its name to Unigold Inc. in December 2002. Unigold Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.